Canadian Agency for Drugs and Technologies in Health. (2018). CADTH Canadian Drug Expert Committee recommendation: Indication : chronic hepatitis C virus infection. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.). CADTH.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Indication : Chronic Hepatitis C Virus Infection. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.). Ottawa (ON): CADTH, 2018.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Indication : Chronic Hepatitis C Virus Infection. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.). CADTH, 2018.
